Background {#Sec1}
==========

The association between hyperuricemia and cardiovascular disease has been well documented for a very long time. However, conflicting results on the correlation between hyperuricemia and the incidence and prognosis of stroke had been reported. In a meta-analysis study, Kim, et al. reported that hyperuricemia increased the risk of both the ischemic stroke and the hemorrhagic stroke as well as the risk of post-stroke mortality \[[@CR1]\]. Several other groups also found that the post-stroke hyperuricemia could significantly exacerbate the outcome of stroke \[[@CR2]--[@CR4]\]. Other study suggested that the effect of pre-stroke hyperuricemia on poor post-stroke outcome, especially in diabetic patients, was still questionable \[[@CR5]\]. Holme and his group also suggested that hyperuricemia might be rather a complementary indicator than an independent risk factor of AS \[[@CR6]\]. Kramer et al. found that the importance of the pre- cardiovascular disease hyperuricemia in predicting cardiovascular disease mortality was only significant in the pre-diabetic and type 2 diabetic patients but not in the normoglycemic patients \[[@CR7]\]. Some investigators even found that post-stroke hyperuricemia might have played a protective role in the prognosis of stroke \[[@CR8]--[@CR12]\]. Miedema et al. found no evidence to support the association between the SUA level and the outcome of stroke in their study \[[@CR13]\].

Hyperuricemia, hyperglycaemia and cardiovascular disease are found to be co-morbid disease \[[@CR14]\]. Hyperuricaemia is also positively associated with prediabetes diagnosed according to impaired fasting glucose criteria other than subjects with normal fasting glucose \[[@CR15]\]. A meta-analysis also ascertain that hyperglycaemia is contributed to the development of diabetes and impaired fasting glucose \[[@CR16]\]. Even in normal range of SUA, uric acid is related to diabetes onset in healthy lean women \[[@CR17]\]. Since the close and complicated association between SUA and prediabetes as stated above and diabetes was a well-known risk factor of stroke \[[@CR18]\], it is in very need to assess and compare the effect of SUA on stroke prognosis stratified by different glycometabolism status. Newman et al. reported that a combination of the post-stroke hyperuricemia and diabetes could significantly increase the risk of adverse events, including recurrent stroke, cardiovascular events even death, in post-stroke patients \[[@CR3]\]. In another study, Zhang et al. found that the post-stroke hyperuricemia was associated with better short-term outcome of stroke in non-diabetes patients \[[@CR12]\]. However they failed to distinguish between the pre-diabetes and the normoglycemia patients in their study. In our study, the association between SUA and the outcome of acute primary stroke would be assessed in both diabetes and normoglycemia patients. The pre-diabetes patients were excluded in our study.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

ACROSS-CHINA" was a large prospective cohort study conducted in China from 2008 to 2009 that investigated on abnormal glucose regulation in acute first-ever stroke (within 14 days), in which a total of 3450 patients with ischemic stroke, intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH) were successively recruited from 34 hospitals across China \[[@CR19], [@CR20]\]. Acute stroke was diagnosed according to World Health Organization combined with CT or MRI confirmation \[[@CR21]\].

All the patients without previous DM were required to perform a standard oral glucose tolerance test (OGTT) at the day 14 ± 3 after stroke onset or before discharge according to the World Health Organization criteria \[[@CR22]\]. Patients were categorized as diabetes, pre-diabetes or normoglycemia according to their OGTT results. One hundred and forty-four patients without SUA values and 399 patients with missing OGTT results were excluded respectively. In the remaining 2,907 patients, there were 1220 diabetics, 777 prediabetics and 910 normoglycaemic patients (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow chart of patient selection. OGTT, oral glucose tolerance test

Data collection {#Sec4}
---------------

Demographic, education degree, tobacco use and alcohol consumption, physical exam and a National Institute of Health Stroke Scale (NIHSS) score were obtained at admission. A detailed history of previous diseases, such as hypertension, coronary artery disease and atrial fibrillation, were also recorded. Body mass index (BMI) was defined as body weight (kg)/the square of height (m). Participants without a history of diabetes were required to take an OGTT test within 24 h after the hospital admission. The lab tests included blood routine test, high density lipoprotein, low density lipoprotein, creatinine, SUA, homocysteine, glucose and insulin level, et al. All the lab tests were performed within 24 h after admission at fasting condition by the certified central laboratory. SUA was measured by the urine enzyme endpoint method. The index of insulin resistance was calculated with the Homeostasis Model Assessment 2- Insulin Resistance (HOMA2-IR) method \[[@CR23]\]. A Modified Rankin Scale (mRS) was calculated in every participant at discharge to evaluate the in-hospital outcome of stroke.

The criteria of diagnosing abnormal glycometabolism {#Sec5}
---------------------------------------------------

The OGTT result and the blood glucose level were used to divide patients into three categorise based on the 1999 World Health Organization (WHO) criteria. The details were as follow: (1) Diabetes mellitus (DM) was defined as fasting plasma glucose (FPG) ≥ 7.0 m mol L^−1^ and/or 2-h value (2-h-value) ≥ 11.1 m mol L^−1^; (2) Pre-diabetes consisted of both impaired glucose tolerance (IGT) and impaired fasting glucose (IFG). IGT was defined as FPG \< 7.0 m mol L^−1^ and a 2-h-value between 7.8 mmol/L and 11.1 m mol L^−1^. IFG was defined as fasting glucose value between 6.1 m mol L^−1^ and 7.0 m mol L^−1^ with a normal 2-h-value; (3) normoglycemia was defined as FPG \< 6.1 m mol L^−1^ and a 2-h-value \< 7.8 m mol L^−1^. Patients who had a history of DM or had ever received hyperglycemic agents for at least 6 months were also assigned to the DM group. All the prediabetics were newly-diagnosed.

Other variables definition {#Sec6}
--------------------------

Tobacco use was categorized as 'current', 'previous' or 'never' smoking. 'Current smoking' was defined as that the individual was an active smoker at the time of the stroke. 'Previous smoking' was defined as that the individual had quit smoking 1 year prior to the stroke. 'Never smoking' was defined as that the individual had never smoked prior to the stroke. Alcohol consumption was categorized as 'never drinking', 'mild drinking','moderate to severe drinking'. 'Moderate or severe drinking' was defined as that the individual consistently consumed ≥2 standard size alcoholic beverages per day. 'Mild drinking' was defined as that the individual consumed \<2 standard size alcoholic beverages per day. 'Never drinking' was defined as that the individual had never consumed any alcoholic beverages. Stroke severity was categorized by the NIHSS score as mild stroke (NIHSS \< 9) or severe stroke (NIHSS ≥ 9) \[[@CR4]\].

Outcome assessment {#Sec7}
------------------

The primary endpoint comprised death and dependency with mRS \>2 \[[@CR24], [@CR25]\]. Death (mRS = 6) was recorded within 14 ± 3 days after admission to the hospital. Dependency (mRS = 3 to 5) was assessed at 14 ± 3 days after the index date of hospital admission or at hospital discharge. Death indicated all-cause death according to the International Classification of Diseases, 10th Revision. Neurological improvement and deterioration were used as supplemental indicators to describe the association between SUA and stroke outcome. Neurological improvement was defined as 4 point decrease in NIHSS during hospitalization or a 0 point status on NIHSS at discharge. Neurological deterioration was defined as 1 point increase in NIHSS during hospitalization \[[@CR24], [@CR26], [@CR27]\].

Statistical analysis {#Sec8}
--------------------

Baseline clinical features were compared stratified by different diabetes diagnosis and functional outcome. All continuous variables were presented as mean ± standard deviation for normal distribution and median (Quartile 1 to 3) for skewed distribution. Kolmogorov-Smirnov test was used for normal distribution test. Categorical variables were presented as frequencies and/or prevalence/incidence rate. For the continuous variables, when the group numbers were more than two, if the variable was normal distribution, one-way ANOVA test was used to perform the comparison (LSD-test for variables with homogeneity of variance and Games-Howell test for variables with heterogeneity of variance), otherwise Kruskal-Wallis H test was performed instead; when the group numbers were just two, if the variable was normal distribution, *T*-test was used to perform the comparison, otherwise Mann--Whitney *U* test was used instead. For categorical variables, the comparisons were used Chi-square test and Fisher exact test. The adjustment of the correlation between different variables was done by multivariate logistic regression. Variables with a *P* value \< 0.1 in univariate analysis were included in the multivariate regression test. Variables, which had shown potential association to the outcome of stroke during the literature search, were also included in the multivariate regression test. The independent factors included in the multivariate analysis were age, gender, education degree, tobacco use, alcohol consumption, BMI, high density lipoprotein, low density lipoprotein, creatinine, systolic and diastolic blood pressure, HOMA2-IR, homocysteine, a history of coronary heart disease, a history of hypertension, a history of atrial fibrillation, stroke types and stroke severity at admission. The use of Aspirin, Diuretics and Coumadin \[[@CR28]\], which could influence SUA concentration, were also analyzed. SUA was compared between "use" and "non-use" of them respectively and stratified by different glycometabolism first, then it will be recognized as a confounding factor if *P \<* 0.05 and entered into the according multivariate analysis. The fitness of the models was evaluated by using the Hosmer and Lemeshow goodness-of-fit test and a P value \> 0.2 was considered as a good fit. All the statistical analyses were done with SPSS ver. 19.0 software (SPSS Inc., Chicago, IL). A *P \<*0.05 was considered statistically significant.

Results {#Sec9}
=======

Comparison of the characteristics of patients in different glucose **metabolism groups** {#Sec10}
----------------------------------------------------------------------------------------

Patients with normoglycemia accounted for 31.3% of the study population. The differences in the characteristics of patients among different groups were shown in Table [1](#Tab1){ref-type="table"}. The normoglycemia group had highest percentage of males (67.7% vs. 64.5%vs. 58.3%, *P \<* 0.001) and higher prevalence of current smoking (*P =* 0.036). The mean level of age in this group was significantly younger than that of the DM or prediabetes group (*P \<* 0.001). In the physical exam and the lab test, the patients in the normoglycemia group had significantly lower blood pressure, BMI, NIHSS score, low density lipoprotein level and HOMA2-IR than that in the DM or prediabetes group (all *P \<* 0.05). The high density lipoprotein, homocysteine in the normoglycemia group were significantly higher than that in the DM or prediabetes group (all *P \<* 0.05). Previous histories of coronary heart disease, hypertension or atrial fibrillation in thenormoglycaemia group were significantly less common than that in the DM group (all *P \<*0.05). Ischemic stroke was the most common type of stroke in all groups, followed by intracerebral hemorrhage and SAH. The percentages of stroke types were significantly different in patients with different glycometabolism status (*P \<*0.001).Table 1Baseline Clinic features according to glycometabolism diagnosis by OGTTClinic featuresDiabetes mellitus (*n =* 1220)Prediabetes (*n =* 777)Normoglycemia (*n =* 910)*P*Age, y (median, Q~1--3~)64 (55, 73)61 (52,72)58 (49, 69))\<0.001Male, *n* (%)711(58.3)501 (64.5%)616 (67.7)\<0.001Tobacco use, *n* (%)0.036 Never712 (58.4)428 (55.1)480 (52.7) Quit110 (9.0)74 (9.5)79 (8.7) Current351 (28.8)246 (31.7)320 (35.2)Alcohol consumption, *n* (%)0.164 Mild213 (17.5)132 (17.0)171 (18.8) Moderate to severe165 (13.5)131 (16.9)152 (16.7) Never817 (67.0)494 (63.6)564 (62.0)BMI, kg/m^2^ (median, Q~1--3~)25.0 (22.9,27.3)24.5 (22.5,26.8)24.2 (22.0,26.2)\<0.001NIHSS (median,Q~1~-Q~3~)5 (2--9)5 (2,9)4 (2--8)0.002Creatinine,m mol L^−1^ (median, Q~1--3~)71.2 (58.0, 87.0)72.0 (60.0, 87.0)71.8 (59.9, 86.7)0.425LDL, m mol L^−1^ (median, Q~1--3~)3.0 (2.4, 3.6)2.9 (2.3, 3.5)2.8 (2.3, 3.4)0.001HDL,m mol L^−1^(median, Q~1--3~)1.1(1.0, 1.3)1.2 (1.0, 1.4)1.2 (1.1, 1.4)\<0.001Systolic blood pressure, mmHg (median, Q~1--3~)150 (138, 160)143 (130, 160)146 (130, 160)\<0.001Homocysteine, μ mol L^−1^, (median, Q~1--3~)14.4 (11.5, 18.7)15.5 (12.0, 21.9)15.7 (12.3, 22.8)\<0.001HOMA2-IR (median, Q~1--3~)2.5 (1.6, 4.0)1.9 (1.1, 3.0)1.6 (0.9, 2.5)\<0.001Past medical history, yes, n (%) Coronary artery disease172 (14.1)87 (11.2)90 (9.9)0.009 Hypertension795 (65.2)470 (60.5)514 (56.5)\<0.001 Atrial fibrillation66 (5.4)54 (6.9)31 (3.4)0.006Stroke types, *n* (%)\<0.001 IS1015 (83.2)541 (69.6)675 (74.2) ICH174 (14.3)185 (23.8)198 (21.8) SAH31 (2.5)51 (6.6)37 (4.1)*OGTT* the oral glucose tolerance test, *BMI* body mass index, *LDL* low density lipoprotein, *HDL* high density lipoprotein, *NIHSS* the National Institutes of Health Stroke Scale, *HOMA2-IR* the correctly solved computer model for homeostasis model assessment of insulin resistance, *IS* ischemic stroke, *ICH* intra-cerebral hemorrhage, *SAH* subarachnoid hemorrhage

Comparison of the characteristics of patients with different functional outcomes of the stroke {#Sec11}
----------------------------------------------------------------------------------------------

There were no significant differences between the favorable outcome group and the poor outcome group in the mean level of age, BMI, HOMA2-IR, low density lipoprotein level, high density lipoprotein level, the prevalence of the histories of coronary heart disease or hypertension. Compared to the favorable outcome group, the mean level of creatinine was significantly lower in the poor outcome group, whereas the blood pressure and homocysteine level were significantly higher in the poor outcome group. The percentage of moderate to severe alcohol consumption as well as the percentage of severe stroke and atrial fibrillation in the poor outcome group was significantly higher than that in favorable outcome group. The percentage of mild drinking was significantly higher in favorable outcome group than that in the poor outcome group. Ischemic stroke was the most common type of stroke in both groups. Cardioembolic ischemic stroke was only accounted for 5.7% (*n =* 91) of the total patients with poor functional outcome. The intracerebral hemorrhage was more commonly seen in the poor outcome group than that in the favorable outcome group while ischemic stroke and SAH were more prevalent in the favorable outcome group. DM was more prevalent in the poor outcome while normoglycemia were more commonly seen in the favorable outcome group (Table [2](#Tab2){ref-type="table"}).Table 2Baseline Clinic features according to poor functional outcomes evaluated by mRS \> 2Clinic featuresFavorable outcomes (*n =* 1305)Poor functional outcomes (*n =* 1602)*P*Age, y60 (52, 71)62 (53, 72)0.003Male, *n* (%)954 (73.1)1089 (68.0)\<0.001Tobacco use, *n* (%)0.036 Never692 (53.0)928 (57.9) Quit126 (9.7)137 (8.6) Current436 (33.4)481 (30.0)Alcohol consumption, *n* (%)0.006 Never811 (62.1)1064 (66.4) Mild266 (20.4)250 (15.6) Moderate to severe192 (14.7)256 (16.0)BMI(kg/m^2^)24.6 (22.5,26.7)24.5 (22.4,26.8)0.637NIHSS scales\<0.001 \<91256 (96.2)996 (62.2) 9--1830 (2.3)474 (29.6)  \> 187 (0.5)124 (7.7)Creatinine (m mol L^−1^)72.7 (60.0, 87.5)70.0 (57.5,85.0)0.002LDL(m mol L^−1^)2.8 (2.3,3.5)2.9 (2.3,3.5)0.290HDL(m mol L^−1^)1.2 (1.0,1.4)1.2 (1.0,1.4)0.125Systolic blood pressure (mmHg)140 (130,160)150 (134,161)\<0.001Homocysteine (μmol L^−1^)14.6 (11.4,19.8)15.8 (12.3,21.4)\<0.001HOMA2-IR1.8 (1.1,3.0)2.0 (1.2,3.1)0.055Past medical history, yes, *n* (%) Coronary heart disease146 (11.2)203 (12.7)0.230 Hypertension785 (60.2)994 (62.0)0.296 Atrial fibrillation53 (4.1)98 (6.1)0.013Stroke types, n (%)\<0.001 Ischemic stroke1059 (81.1)1172 (73.2)\<0.001 Cardioembolic44 (3.4)91 (5.7) Large-artery atherosclerosis565 (43.3)819 (51.1) Small-artery occlusion Lacunar367 (28.1)200 (12.5) Other demonstrated or undemonstrated38 (2.9)25 (1.6) ICH176 (13.5)381(23.8) SAH70 (5.4)49 (3.1)Glycometabolism status**\<0.001** Diabetes mellitus500 (38.3)720 (44.9) Prediabetes348 (26.7)429 (26.8) Normoglycaemia457 (35.0)453 (28.3)*mRS* modified Rankin scale, *BMI* body mass index, *LDL* low density lipoprotein, *HDL* high density lipoprotein, *NIHSS* the National Institutes of Health Stroke Scale, *HOMA2-IR* the correctly solved computer model for homeostasis model assessment of insulin resistance, *IS* ischemic stroke, *ICH* intra-cerebral hemorrhage, *SAH* subarachnoid hemorrhage

Analysis on medication use and SUA concentration {#Sec12}
------------------------------------------------

There are 1542 patients with data on aspirin, 20 patients on Coumadin and 124 patients on Diuretics. SUA levels were compared between "use" and "non-use" of them respectively and stratified by different glycometabolism. After that a significant association was found between Aspirin use and SUA level among normal glycemic stroke patients (Additional file [1](#MOESM1){ref-type="media"}: Table S3, Additional file [2](#MOESM2){ref-type="media"}: Table S4 and Additional file [3](#MOESM3){ref-type="media"}: Table S5). Aspirin use was then entered into the multivariate analysis on SUA and the outcome among normoglycaemic stroke patients.

Correlation between SUA and poor functional outcome at discharge {#Sec13}
----------------------------------------------------------------

### Univariate analysis of SUA quartiles on poor outcome {#Sec14}

The patients were divided into quartile groups (Q1 to Q4) based on their SUA level. The concentrations of SUA in these groups were as follow: Q1 \< 221 μmol L^−1^, Q2 221-286 μmol L^−1^, Q3 286-352 μmol L^−1^ and Q4 \> 352 μmol L^−1^ (DM group, N~Q1=~307, N~Q2~ = 306, N~Q3~ = 310, N~Q4~ = 291; Prediabetes group, N~Q1=~184, N~Q2~ = 198, N~Q3~ = 190, N~Q4~ = 198; Normoglycaemia group, N~Q1=~229, N~Q2~ = 218, N~Q3~ = 211, N~Q4~ = 248). In both diabetic and normoglycemic strokes, the occurrence of stroke poor outcome decreased across the increasing SUA levels from Q1 to Q4(*P =* 0.019 in DM, 0.016 in normoglycemia), however, it didn't differ in SUA quartiles in prediabeteic strokes (*P =* 0.110 in prediabetes) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Poor outcome rates depending on serum uric acid quartiles stratified by glycometabolism status. OGTT, the oral glucose tolerance test. Q1-4 indicates serum uric acid levels by quartiles. Q1 to Q4 were Q1, \<221 μmol L^−1^; Q2, (221--286) μmol L^−1^; Q3, (286--352) μmol L^−1^ and Q4, \>352 μmol L^−1^

Multivariate analysis of SUA quartiles on poor functional outcome at discharge {#Sec15}
------------------------------------------------------------------------------

To further evaluate the correlation between the SUA level and the poor post-stroke outcome, the SUA level along with other potential risk factors of poor post-stroke outcome were introduced into a regression model as independent variables and the multivariate logistic regression was used to assess the adjusted correlation between the SUA level and the outcome of stoke. The NIHSS score was entered into the regression model as an ordinal variable with the cut-off point of 9 first and then as a continuous one.

The final results of the regression showed that there was a negative correlation between the SUA level and the occurrence rate of poor outcome of stroke in normoglycemic group. In the normoglycemic group, the occurrence rate of poor outcome in Q1 group was also significantly higher than that in the Q4 group (OR = 3.79, 95% CI 1.23--8.67, *P =*0.020) (Fig. [3](#Fig3){ref-type="fig"}); In DM group, the possibility of poor outcome in lowest SUA group (Q1) was significantly higher than that in Q4 (OR = 2.07, 95% CI 1.05--4.08). The possibility of poor outcome in Q2 and Q3 groups were not significantly higher than that in Q4 (Q2: OR = 1.33, 95% CI 0.71--2.47; Q3: OR = 1.79, 95% CI 0.99--3.26). In prediabetes, the possibility of poor outcome did not differ in SUA quartiles (all *P \>* 0.05). The Hosmer and Lemeshow goodness-of-fit test results (*χ* ^2^, P) were (8.839, 0.356), (110.982, 0.215) and (4.558, 0.755) in the DM, prediabetes and the normoglycemia group, respectively (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Association between uric acid quartiles and poor outcomes in multivariate logistic regression analysis ^a^ (^**a**^ adjusted for age, gender, stroke types, tobacco use, alcohol consumption, education level received, a history of hypertension, coronary artery disease or atrial fibrillation, NIHSS \<9 VS ≥9, body mass index, homocysteine, systolic blood pressure, diastolic blood pressure, HOMA-IR, low density lipoprotein, high density lipoprotein, creatinine. In normoglycaemic subjects, Aspirin use was included as a binary variable in the analysis). NIHSS indicates the National Institutes of Health Stroke Scale; HOMA2-IR indicates the correctly solved computer model for homeostasis model assessment of insulin resistance

In normoglycaemic stroke patients, NIHSS was then entered as a continuous variable into multivariate analysis instead of NIHSS as a binary variable. The association was still significant after the new adjustment (Additional file [4](#MOESM4){ref-type="media"}: Table S7).

In normoglycaemic stroke patients, further analysis was performed stratified by sex (Additional file [5](#MOESM5){ref-type="media"}: Table S6). There was 620 male and 290 female in normoglycaemic group. In male, after adjusted for the same variables as the above, the lowest level of SUA is still an independent risk factor for the poor functional outcome (OR with 95% CI 5.06(1.17--12.05), *P =* 0.031). However it was not the case in female patients (OR with 95% CI 9.21(0.98--38.66), *P =* 0.158).

Multivariate analysis of SUA deciles on poor functional outcome {#Sec16}
---------------------------------------------------------------

SUA was re-divided into decile groups (D1 to D10) in different glucose metabolism groups. The SUA quartile groups in previous regression model were replaced with SUA deciles and a new regression model was calculated. The ORs of the incidence rate of poor outcome obtained from the regression model were used in the curve-fitting analysis. The curve-fitting results showed a U-shape curve and the cubic curve had the highest R^2^ value in both the DM group and the normoglycemia group (Fig. [4a](#Fig4){ref-type="fig"} and [c](#Fig4){ref-type="fig"}). The occurrence of poor outcome significantly decreased across SUA deciles from D1 to D9 in both normoglycemia and DM strokes (P for trend0.003 and 0.010, respectively), while it did not differ from D1-10 in prediabetes group (Fig. [4](#Fig4){ref-type="fig"} b, P for trend, 0.568).Fig. 4Association between serum uric acid deciles and poor outcomes in multivariate logistic regression analysis^a^ (^**a**^ adjusted for the same variables as those in Fig. [3](#Fig3){ref-type="fig"}). **\***indicates the reference OR (the OR of D10 = 1). Reference point not included as basis for fit of regression lines. D1-10 indicates 1st decile to the 10th decile of serum uric acid. D1 to D10 (μmol L^−1^) in 'Diabetes' were \<169, 169--206, 206--235, 235--261, 261--286, 286--308, 308--334, 334--368, 368--424, \>424. D1 to D10 (μmol L^−1^) in "Prediabetes" were \<155, 155--208, 208--237, 237--266, 266--287, 287--314, 314--342, 342--380, 380--438, \>438. D1-10 (μmol L^−1^) in 'Normoglycaemia' were \<151, 151--201, 201--235, 235--260, 260--288, 288--316, 316--343, 343--381, 381--425, \>425

Multivariate analysis of continuous SUA concentration on poor functional outcome {#Sec17}
--------------------------------------------------------------------------------

SUA were further reintroduced into the multivariate analysis as a continuous variable. After adjusting for the same confounding factors as the above, higher SUA was still significantly independently associated with the less possibility of poor outcome in patients with normoglycaemia, while the association did not exist in patients with DM or prediabetes (Table [3](#Tab3){ref-type="table"}). The Hosmer and Lemeshow goodness-of-fit test results (*χ* ^2^, P) were (9.873, 0.274) in DM, (4.719, 0.787) in prediabetes and (5.621, 0.690) in normoglycemia group, respectively.Table 3Association between SUA as a continuous variable and poor outcome stratified by glycometabolism status^a^Glycometabolism statusOdds ratio with 95% confidence intervals*P*Diabetes mellitus0.98 (0.97--1.00)0.135Prediabetes1.00 (1.00--1.01)0.105Normoglycaemia0.99 (0.98--1.00)0.022^a^adjusted for the same variables as those in Fig. [3](#Fig3){ref-type="fig"}

SUA concentration and Neurological functional change stratified by glycometabolism {#Sec18}
----------------------------------------------------------------------------------

### SUA and Neurological improvement {#Sec19}

In diabetic and prediabetic stroke patients, SUA quartiles were significantly associated with neurological improvement. Patients with the lowest level of SUA (\<221umol/L) occupied 28.5% and 30.6% within the diabetes and prediabetes being neurological improved (both *P \<*0.05. Additional file [6](#MOESM6){ref-type="media"}: Table S1. Additional file [7](#MOESM7){ref-type="media"}: Figure S1).

### SUA and Neurological deterioration {#Sec20}

There were no significant association between SUA and neurological deterioration in all the glycometabolism statuses (Additional file [8](#MOESM8){ref-type="media"}: Table S2. Additional file [9](#MOESM9){ref-type="media"}: Figure S2).

Correlation between SUA levels and stroke severity at admission {#Sec21}
---------------------------------------------------------------

The correlation between stroke severity (NIHSS \< 9, 9--18,\>18) and the SUA level was also analyzed. The patients were divided into 3 groups according to NIHSS of \<9, 9--18 and \>18, respectively. The correlation between stroke severity and the SUA quartile was calculated (Fig. [5](#Fig5){ref-type="fig"}). In DM and prediabetes, the percentage of patients with low SUA (Q1) in the severe stroke group (NIHSS \> 18) was significantly higher than that in the mild stroke group (NIHSS \< 9) (*P \<* 0.001for DM and 0.023 for prediabetes). There were no significant differences in the SUA level across different stroke severity in the normoglycemia group (*P =* 0.066).Fig. 5Association between serum uric acid levels and stroke severity stratified by glycometabolism status. SUA indicates serum uric acid. NIHSS indicates the National Institutes of Health Stroke Scale

Other variables associated with the poor functional outcome of the stroke in multivariate analysis {#Sec22}
--------------------------------------------------------------------------------------------------

NIHSS ≥9 was a significant risk factor of the poor outcome in all patients (In diabetes, 12.15 (8.08--18.21); In prediabetes, 11.58 (7.50--23.25); In normoglycemia, 18.40 (7.90--25.45)). In normoglycemia group, higher BMI as well as higher systolic blood pressure were also related to significantly higher risk of poor outcome (BMI 1.09 (1.02--1.18), systolic blood pressure 1.02 (1.01--1.18)).

Discussion {#Sec23}
==========

Most of previous studies suggested that hyperuricemia was a risk factor of stroke. In the present study, SUA values in predicting poor functional outcomes after stroke differed in 3 glycometabolism statuses. Lower SUA level (SUA \< 220 μmol L^−1^) was an independent risk predictor of the short-term prognosis of the acute first-ever stroke in patients with normoglycemia other than DM or prediabetes and such an effect might has gender difference. In the present study, the relationship is much more robust in male than in female normoglycaemic stroke patients.

Difference in the association of SUA level and post-stroke poor functional outcome among different glycometabolism status {#Sec24}
-------------------------------------------------------------------------------------------------------------------------

The correlation between the SUA level and the poor post-stroke outcome in the normoglycemia patients was different from that in the DM or prediabetes patients in our study. Low SUA level was an independent predictor of the poor outcome of stroke in the normoglycemia patients but not in DM or prediabetes group. In DM group, a paradox association was found: 1) the association between the lowest SUA quartile (Q1) and the poor outcome was observed as significant (Fig. [3](#Fig3){ref-type="fig"}. *P =* 0.032) but the trend from Q1-Q4 was not (Fig. [3](#Fig3){ref-type="fig"}. P for trend = 0.109); 2) the association between SUA deciles and poor outcome was in a significant trend (Fig. [4](#Fig4){ref-type="fig"} a. P for trend 0.003); 3) however, the significant association disappeared when assessment was performed between the continuous SUA concentration and the poor outcome (Table [3](#Tab3){ref-type="table"} . *P =* 0.135). In prediabetes group, possibility of poor outcome in the lower SUA levels was similar to that in the higher SUA levels either SUA was introduced into the multivariate analysis as a categorical variable or a continuous variable.

These debated results might be attributed to the negative association between SUA levels and stroke severity in DM and prediabetes (Fig. [5](#Fig5){ref-type="fig"} a and b. *P \<* 0.001 for DM and 0.023 for prediabetes). The percentage of the lower SUA level was significantly increased across the aggravated stroke severity in diabetes and prediabetes group, and stroke severity (measured as NIHSS level) was also significantly associated with the poor outcome in the multivariate analysis, we speculated that the effect of the low SUA level in DM on the poor outcome of stroke might be carried out via its correlation with the severity of stroke. On the contrary, based on the fact that there was no correlation between the SUA level and the severity of stroke in normoglycemia patients (Fig. [5c](#Fig5){ref-type="fig"}. *P =* 0.066), the association of SUA and poor outcome was independent of stroke severity at baseline in normoglycemia patients. Therefore, SUA in normoglycaemia was an independent risk factor of poor outcome, whereas SUA in DM was only a complementary but not an independent one.

Zhang et al. reported their findings of a similar study in 2012 \[[@CR12]\]. The correlation between the SUA level and the poor outcome of stroke in patients with normoglycemia and DM in their study was in line with us; Although the patients in their study were young and mid-age adults (18--45 years old) which was different with us (from 18 to 85 years old), the results were similar. It is a pity that they did not differentiate the prediabetes patients from the 'real' normoglycemia patients. Further than their research, we examine the association in prediabetes. Though we did not found a significant association between SUA and poor outcome in prediabetes, concerning the results that the association was much more significant and prominent in normoglycaemia patients than those with abnormal glycometabolism, it was highly implied that glucose metabolism might deeply affect the influence of SUA on post-stroke short-term outcome.

Till now, the effect of SUA on the prognosis of stroke in abnormal glucose metabolism is still debatable. Kramer et al. in their 2010 study reported that hyperuricemia was a significant risk factor for the mortality of cardiovascular disease in patients with pre-diabetes and typeIIdiabetes, but it did not increase the risk of mortality in patients with normoglycemia \[[@CR7]\]. Their findings contradicted to our results. The conflicting results might be caused by the different race (Caucasian vs. Chinese) and age (mid-age to elders vs. 18 to 85) of the participants as well as the different sampling time of SUA (pre-event vs. post-event different phases).

Gender difference is attributed to SUA concentration \[[@CR29], [@CR30]\], thus effect of SUA on poor functional outcome differs in gender. There is no significant association found in female subgroup in the present study, which is mainly caused by the not large enough sample size (only 290 female stroke patients with normoglycaemia).

The possible mechanisms of the association between post-stroke SUA levels and the outcomes after stroke {#Sec25}
-------------------------------------------------------------------------------------------------------

There were conflicting results about the association between the post-stroke SUA level and the prognosis of stroke in the literature. Several studies reported that hyperuricemia was a risk factor for the poor outcomes \[[@CR2]--[@CR4]\] and suggested that the follow adverse effects of uric acid on the cardiovascular system might be the underline reasons: first, Hyperuricemia could cause insulin resistance \[[@CR31]\]; second, hyperuricemia could increase the risk of hypertension and further aggravated atherosclerosis \[[@CR32]\]; third, hyperuricemia could directly or indirectly impair the self-regulation of the arteriole and increased the risk of stroke \[[@CR33]\].

At the meanwhile, results from other studies suggested hyperuricaemia might be a protective factor of stroke \[[@CR8]--[@CR12], [@CR34]\]. Most of them \[[@CR8], [@CR10]--[@CR12], [@CR34]\] were published after the meta-analysis study from Kim, et al. \[[@CR1]\]. In another study, administration of uric acid during the thrombolysis procedure in acute ischemic stroke patients had been proven to be neuro-protective \[[@CR35]\]. It had also been proven in another study that low SUA was associated with larger infarction area and worse neurological deficit in the stroke patients \[[@CR36]\]. The possible mechanisms of this protective effect of SUA included: (1) SUA was one of the most important serum antioxidant factors and an anti-inflammatory factor \[[@CR37]--[@CR40]\]; (2) SUA could stabilize endothelia progenitor cells (EPCs) \[[@CR41]\]; (3) SUA could decrease the degradation of the extracellular superoxide dismutase-3(SOD~3~) \[[@CR42]\]; (4) In the chronic disease, hyperuricaemia was a reaction of the negative feedback mechanism to counterbalance the increased level of reactive oxygen species (ROS) \[[@CR43]\]. It had been proven that Xanthine Oxidase (XO) expression increased after acute ischemic cerebral lesion and the increased XO would further lead to the uric acid level in local brain tissue to increase significantly. The rate of the change in XO and local uric acid level was positively correlated with the severity of the ischemic damage of the brain tissue \[[@CR44], [@CR45]\]. In 2010, Brouns, et al. reported the rate of SUA decrease in the first 7 days after stroke was positively correlated with the severity of the stroke as well as the incidence rate of poor post-stroke outcome \[[@CR46]\]. Therefore, the concentration of peripheral SUA post stroke is most possibly in a dynamically decreasing pattern but it is still unknown exactly.

This dynamically decreasing pattern of SUA post stroke would attribute to the contradictory results on SUA and poor outcome. Of all the researches, SUA values from the different measurement timing post stroke (some were within 3 days, some were within 14 days, others were within several hours, etc.) could not stand for the SUA level in a concordant post-stroke phase. Since its dynamic changes, the association of SUA and poor outcome was altered concerning a specific population (poor outcome or favorable outcome). For example, as for the patients with poor outcome, when the timing of SUA evaluated was just at the phase of higher SUA level, we might find an adverse effect of SUA on poor outcome, otherwise the effect might find to be protective. Therefore, the diverse investigations on SUA at different phases post stroke might come to paradox results. Further investigation needs to be carried out on figuring out the pattern of SUA concentration post stroke and its association as well the abnormal glucose metabolism on poor prognosis.

Advantages and limitations {#Sec26}
--------------------------

ACROSS-CHINA is a nationwide, prospective, multiple-center study. In our study, pre-diabetic patients were excluded by OGTT test result to eliminate their possible interference to the results. There were some limitations in our study. First, only patients with SUA data were included in the study and this might cause selection bias. Second, there were no data of the dynamic change of SUA level. Third, only a few data on medications that might affect the SUA level were collected and no data on non-VKA oral anticoagulants (NOACs). Fourth, lack of data on exercise pre- and post- stroke. Exercise is also a major factor to influence SUA concentration \[[@CR47]\].

Conclusions {#Sec27}
===========

The associations between post-stroke SUA and poor functional outcome at discharge differ in diverse abnormal glycometabolism populations. In acute stroke patients with normoglycemia, low SUA level (\<220 μmol L-1) is an independent risk predictor of poor short-term outcome other than DM or prediabetes. The debated conclusion on the association between SUA and the poor outcome after stroke might be due to the diverse post-stroke time of blood sample for SUA in those different studies. Further research will be conducted on the association between the pattern of SUA change in stroke patients with different time of stroke onset, different glycoemtabolism status, different gender, through recording the dynamic value of SUA post stroke and the poor functional outcome and stratifying the study group by diagnosing glycometabolism status.
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